Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study

Roberto Latagliata, Dario Ferrero, Alessandra Iurlo, Francesco Cavazzini, Fausto Castagnetti, Elisabetta Abruzzese, Carmen Fava, Massimo Breccia, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Giovanna Mansueto, Antonella Gozzini, Sabina Russo, Laura Cavalli, Enrico Montefusco, Gabriele Gugliotta, Michele Cedrone, Antonella Russo RossiPaolo Avanzini, Patrizia Pregno, Endri Mauro, Antonio Spadea, Francesca Celesti, Gianfranco Giglio, Alessandro Isidori, Monica Crugnola, Elisabetta Calistri, Federica Sorà, Stefano Storti, Ada D'Addosio, Giovanna Rege-Cambrin, Luigiana Luciano, Giuliana Alimena

Research output: Contribution to journalArticlepeer-review

Abstract

Background: A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries. Patients and Methods: To describe the safety and tolerability of imatinib in very elderly CML patients in chronic phase, 211 chronic-phase CML patients aged >75 years were retrospectively analyzed using data collected from 31 institutions in Italy. Results: The median age at imatinib start was 78.6 years [interquartile range (IR) 76.3-81.4], median time from diagnosis to imatinib start was 1.2 months (IR 0.5-3.7). The starting dose of imatinib was 400 mg/day in 144 patients (68.2 %), >400 mg/day in 4 patients (2.0 %), and

Original languageEnglish
Pages (from-to)629-637
Number of pages9
JournalDrugs and Aging
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2013

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study'. Together they form a unique fingerprint.

Cite this